Literature DB >> 18786498

Preventing and managing the side effects of isotretinoin.

Megan Brelsford1, Trisha Clarke Beute.   

Abstract

Isotretinoin (13-cis-retinoic acid) is widely used for the treatment of severe acne as well as for disorders of conification, for psoriasis, and for skin cancer prevention. As a member of the retinoid family, it has a wide spectrum of side effects, including reproductive, cutaneous, ocular, neurological, musculoskeletal, and hepatic. As long as patients are able to tolerate these side effects, it can be a very effective treatment option. This article examines both the most common and the most concerning side effects as well as ways in which providers and patients may best manage them to be able to benefit from isotretinoin treatment.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18786498     DOI: 10.1016/j.sder.2008.07.002

Source DB:  PubMed          Journal:  Semin Cutan Med Surg        ISSN: 1085-5629


  20 in total

1.  Severe ulcerated 'bodybuilding acne' caused by anabolic steroid use and exacerbated by isotretinoin.

Authors:  Verena Voelcker; Michael Sticherling; Jürgen Bauerschmitz
Journal:  Int Wound J       Date:  2010-06       Impact factor: 3.315

2.  Isotretinoin use and compliance with the Dutch Pregnancy Prevention Programme: a retrospective cohort study in females of reproductive age using pharmacy dispensing data.

Authors:  Martina Teichert; Loes E Visser; Mark Dufour; Eline Rodenburg; Sabine M J M Straus; Peter A G M De Smet; Bruno H Ch Stricker
Journal:  Drug Saf       Date:  2010-04-01       Impact factor: 5.606

Review 3.  Ocular toxicity from systemically administered xenobiotics.

Authors:  Mitan R Gokulgandhi; Aswani Dutt Vadlapudi; Ashim K Mitra
Journal:  Expert Opin Drug Metab Toxicol       Date:  2012-07-18       Impact factor: 4.481

4.  All-Trans-Retinoic Acid Enhances Mitochondrial Function in Models of Human Liver.

Authors:  Sasmita Tripathy; John D Chapman; Chang Y Han; Cathryn A Hogarth; Samuel L M Arnold; Jennifer Onken; Travis Kent; David R Goodlett; Nina Isoherranen
Journal:  Mol Pharmacol       Date:  2016-02-26       Impact factor: 4.436

5.  A CYP26B1 polymorphism enhances retinoic acid catabolism and may aggravate atherosclerosis.

Authors:  Olesya Krivospitskaya; Ali Ateia Elmabsout; Eva Sundman; Leif A Söderström; Olga Ovchinnikova; Andreas C Gidlöf; Nikolai Scherbak; Giuseppe Danilo Norata; Ann Samnegård; Hans Törmä; Samy M Abdel-Halim; Jan-Håkan Jansson; Per Eriksson; Allan Sirsjö; Peder S Olofsson
Journal:  Mol Med       Date:  2012-05-09       Impact factor: 6.354

6.  Structural and Functional Assessment in Patients Treated with Systemic Isotretinoin Using Optical Coherence Tomography and Frequency-Doubling Technology Perimetry.

Authors:  Berker Bakbak; Sansal Gedik; Bengu Ekinci Koktekir; Huseyin Guzel; Hilmi Cevdet Altınyazar
Journal:  Neuroophthalmology       Date:  2013-05-31

7.  Isotretinoin use and the risk of inflammatory bowel disease: a population-based cohort study.

Authors:  Raed O Alhusayen; David N Juurlink; Muhammad M Mamdani; Richard L Morrow; Neil H Shear; Colin R Dormuth
Journal:  J Invest Dermatol       Date:  2012-10-25       Impact factor: 8.551

8.  Repression of hepatocyte nuclear factor 4 alpha by AP-1 underlies dyslipidemia associated with retinoic acid.

Authors:  Kyoung-Jae Won; Joo-Seop Park; Hyunyoung Jeong
Journal:  J Lipid Res       Date:  2019-02-01       Impact factor: 5.922

9.  Retinoic acid represses CYP7A1 expression in human hepatocytes and HepG2 cells by FXR/RXR-dependent and independent mechanisms.

Authors:  Shi-Ying Cai; Hongwei He; Trong Nguyen; Albert Mennone; James L Boyer
Journal:  J Lipid Res       Date:  2010-03-25       Impact factor: 5.922

10.  Awareness of isotretinoin use and Saudi FDA pregnancy prevention program in Riyadh, Saudi Arabia: A cross-sectional study among female patients.

Authors:  Alnada Abdalla Mohamed Ibrahim; Amal Almotiry Alshatri; Salem Alsuwaidan; Lulu Almutairi; Nasser Aljasser; Mansour Adam Mahmoud; Afnan Alaseeri; Abrar Almonysir; Badraa Alotaibi; Batoul Alrasheed; Maram Alfawaz
Journal:  Saudi Pharm J       Date:  2021-04-23       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.